Cargando…

Correction to: Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration

Detalles Bibliográficos
Autores principales:	Duffy, Megan F., Collier, Timothy J., Patterson, Joseph R., Kemp, Christopher J., Luk, Kelvin C., Tansey, Malú G., Paumier, Katrina L., Kanaan, Nicholas M., Fischer, D. Luke, Polinski, Nicole K., Barth, Olivia L., Howe, Jacob W., Vaikath, Nishant N., Majbour, Nour K., El-Agnaf, Omar M. A., Sortwell, Caryl E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5975483/ https://www.ncbi.nlm.nih.gov/pubmed/29843738 http://dx.doi.org/10.1186/s12974-018-1202-9

Ejemplares similares

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration
por: Duffy, Megan F., et al.
Publicado: (2018)

Impact of age and vector construct on striatal and nigral transgene expression
por: Polinski, Nicole K, et al.
Publicado: (2016)

α‐Synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies
por: van Steenoven, Inger, et al.
Publicado: (2018)

Structural and Biophysical Characterization of Stable Alpha-Synuclein Oligomers
por: Vaikath, Nishant, et al.
Publicado: (2022)

Investigating the presence of doubly phosphorylated α‐synuclein at tyrosine 125 and serine 129 in idiopathic Lewy body diseases
por: Fayyad, Muneera, et al.
Publicado: (2020)

Silencing Alpha Synuclein in Mature Nigral Neurons Results in Rapid Neuroinflammation and Subsequent Toxicity
por: Benskey, Matthew J., et al.
Publicado: (2018)

Novel engineered nanobodies specific for N‐terminal region of alpha‐synuclein recognize Lewy‐body pathology and inhibit in‐vitro seeded aggregation and toxicity
por: Hmila, Issam, et al.
Publicado: (2022)

Increased levels of CSF total but not oligomeric or phosphorylated forms of alpha-synuclein in patients diagnosed with probable Alzheimer’s disease
por: Majbour, Nour K., et al.
Publicado: (2017)

Fibrillar form of α-synuclein-specific scFv antibody inhibits α-synuclein seeds induced aggregation and toxicity
por: Gupta, Vijay, et al.
Publicado: (2020)

Subthalamic Nucleus Deep Brain Stimulation Does Not Modify the Functional Deficits or Axonopathy Induced by Nigrostriatal α-Synuclein Overexpression
por: Fischer, D. Luke, et al.
Publicado: (2017)

Quality Over Quantity: Advantages of Using Alpha-Synuclein Preformed Fibril Triggered Synucleinopathy to Model Idiopathic Parkinson’s Disease
por: Duffy, Megan F., et al.
Publicado: (2018)

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2014)

Microglial depletion does not impact alpha-synuclein aggregation or nigrostriatal degeneration in the rat preformed fibril model
por: Stoll, Anna C., et al.
Publicado: (2023)

CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers
por: Majbour, Nour K., et al.
Publicado: (2020)

Best Practices for Generating and Using Alpha-Synuclein Pre-Formed Fibrils to Model Parkinson’s Disease in Rodents
por: Polinski, Nicole K., et al.
Publicado: (2018)

Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson’s disease
por: Majbour, Nour K., et al.
Publicado: (2016)

Disease-Associated α-Synuclein Aggregates as Biomarkers of Parkinson Disease Clinical Stage
por: Majbour, Nour, et al.
Publicado: (2022)

Substantia nigral dopamine transporter uptake in dementia with Lewy bodies
por: Lee, Young-gun, et al.
Publicado: (2023)

A novel multiplex assay for simultaneous quantification of total and S129 phosphorylated human alpha-synuclein
por: Landeck, Natalie, et al.
Publicado: (2016)

Natural Alkaloid Compounds as Inhibitors for Alpha-Synuclein Seeded Fibril Formation and Toxicity
por: Ghanem, Simona S., et al.
Publicado: (2021)

Cerebrospinal Fluid α-Synuclein Species in Cognitive and Movements Disorders
por: Constantinides, Vasilios C., et al.
Publicado: (2021)

Analysis of inflammation-related nigral degeneration and locomotor function in DJ-1(−/−) mice
por: Nguyen, Thi A, et al.
Publicado: (2013)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Nitrated α–Synuclein Immunity Accelerates Degeneration of Nigral Dopaminergic Neurons
por: Benner, Eric J., et al.
Publicado: (2008)

The Nigral Coup in Parkinson’s Disease by α-Synuclein and Its Associated Rebels
por: Sian-Hulsmann, Jeswinder, et al.
Publicado: (2021)

Expression, purification and characterization of α-synuclein fibrillar specific scFv from inclusion bodies
por: Gupta, Vijay, et al.
Publicado: (2020)

RT-QuIC Using C-Terminally Truncated α-Synuclein Forms Detects Differences in Seeding Propensity of Different Brain Regions from Synucleinopathies
por: Poggiolini, Ilaria, et al.
Publicado: (2021)

Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice
por: Karampetsou, Mantia, et al.
Publicado: (2017)

Assessment of Aggregated and Exosome-Associated α-Synuclein in Brain Tissue and Cerebrospinal Fluid Using Specific Immunoassays
por: Anagnostou, Dimitrios, et al.
Publicado: (2023)

Nigral overexpression of alpha-synuclein in the absence of parkin enhances alpha-synuclein phosphorylation but does not modulate dopaminergic neurodegeneration
por: Van Rompuy, Anne-Sophie, et al.
Publicado: (2015)

α-Synuclein phosphorylation at serine 129 occurs after initial protein deposition and inhibits seeded fibril formation and toxicity
por: Ghanem, Simona S., et al.
Publicado: (2022)

α-Synuclein antisense oligonucleotides as a disease-modifying therapy for Parkinson’s disease
por: Cole, Tracy A., et al.
Publicado: (2021)

PGC-1α activity in nigral dopamine neurons determines vulnerability to α-synuclein
por: Ciron, Carine, et al.
Publicado: (2015)

Dopaminergic Positron Emission Tomography Imaging in the Alpha‐Synuclein Preformed Fibril Model Reveals Similarities to Early Parkinson's Disease
por: Sossi, Vesna, et al.
Publicado: (2022)

α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis
por: Butkovich, Laura M., et al.
Publicado: (2018)

Dihydromyricetin and Salvianolic acid B inhibit alpha-synuclein aggregation and enhance chaperone-mediated autophagy
por: Wu, Jia-Zhen, et al.
Publicado: (2019)

Inhibition of alpha-synuclein seeded fibril formation and toxicity by herbal medicinal extracts
por: Ardah, Mustafa T., et al.
Publicado: (2020)

Beta2-adrenoreceptor agonist clenbuterol produces transient decreases in alpha-synuclein mRNA but no long-term reduction in protein
por: Patterson, Joseph R., et al.
Publicado: (2022)

Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
por: Parnetti, Lucilla, et al.
Publicado: (2014)

CSF or serum neurofilament light added to α‐Synuclein panel discriminates Parkinson's from controls
por: Oosterveld, Linda P., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ggqabbajag46kt6n1n94lstosq